In the case of ALK-positive, 2-year treatment with alectinib has been shown to clearly improve DFS compared to standard adjuvant chemotherapy in patients with stage IB (≥4 cm)–IIIA non-small cell lung cancer resection. Here, ALK is linked to non-small cell lung carcinoma.